FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313325428> ?p ?o ?g. }

• W4313325428 endingPage "e2248803" @default.
• W4313325428 startingPage "e2248803" @default.
• W4313325428 abstract "Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Hepatotoxic effects, including hyperbilirubinemia and elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, are common during all phases of therapy and are linked to several chemotherapeutic agents, including asparaginase, mercaptopurine, and methotrexate.To determine which genetic variants were associated with hyperbilirubinemia and elevated ALT and AST levels in children, adolescents, and young adults treated for ALL.This retrospective analysis of a multiethnic genome-wide association study was conducted between January 1, 2019, and April 15, 2022, including patients treated as part of Children's Oncology Group (COG) trials with centers in the United States, Canada, and Australia, which accrued data from December 29, 2003, to January 21, 2011 (AALL0232), and from January 22, 2007, to July 24, 2014 (AALL0434). Germline genotypes were interrogated using genome-wide arrays and imputed using a National Institutes of Health TOPMed Imputation server. Mixed-effects logistic regressions were used to account for multiple episodes for an individual patient. Genotype × treatment phase interaction was tested to uncover phase-specific genetic risk factors.Total duration of multiagent protocol chemotherapy ranging from 2.5 to 3.5 years.The primary outcomes were National Cancer Institute Common Terminology Criteria for Adverse Events (version 4) hyperbilirubinemia of grade 3 or higher and elevated liver ALT and AST levels.A total of 3557 participants were included in the analysis (2179 [61.3%] male; median age, 11.1 [range, 1-30] years). Among 576 known variants associated with these liver function test results in the general population, UGT1A1 variant rs887829 and PNPLA3 variant rs738409 were associated with increased risk of hyperbilirubinemia (odds ratio [OR], 2.18 [95% CI, 1.89-2.53]; P = 6.7 × 10-27) and ALT and AST levels (OR, 1.27 [95% CI, 1.15-1.40]; P = 3.7 × 10-7), respectively, during treatment for ALL. Corresponding polygenic risk scores were associated with hepatotoxic effects across all therapy phases and were largely driven by UGT1A1 and PNPLA3 variants. Genome-wide association analysis revealed an age-specific variant near the CPT1A gene that was only associated with elevated ALT and AST levels among patients younger than 10 years (OR, 1.28 [95% CI, 1.18-1.39]; P = 8.7 × 10-10).These results suggest a strong genetic basis for interpatient variability in hyperbilirubinemia and aminotransferase level elevations during leukemia chemotherapy." @default.
• W4313325428 created "2023-01-06" @default.
• W4313325428 creator A5009866488 @default.
• W4313325428 creator A5010840699 @default.
• W4313325428 creator A5015357573 @default.
• W4313325428 creator A5023214494 @default.
• W4313325428 creator A5024573751 @default.
• W4313325428 creator A5035759509 @default.
• W4313325428 creator A5045792195 @default.
• W4313325428 creator A5048454024 @default.
• W4313325428 creator A5056916024 @default.
• W4313325428 creator A5061175007 @default.
• W4313325428 creator A5061426227 @default.
• W4313325428 creator A5061781141 @default.
• W4313325428 creator A5069884819 @default.
• W4313325428 creator A5080485119 @default.
• W4313325428 creator A5085010022 @default.
• W4313325428 date "2022-12-29" @default.
• W4313325428 modified "2023-09-30" @default.
• W4313325428 title "Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia" @default.
• W4313325428 cites W1489703979 @default.
• W4313325428 cites W1891689427 @default.
• W4313325428 cites W1974526584 @default.
• W4313325428 cites W2017511982 @default.
• W4313325428 cites W2069403407 @default.
• W4313325428 cites W2077770672 @default.
• W4313325428 cites W2081433238 @default.
• W4313325428 cites W2134118606 @default.
• W4313325428 cites W2146949579 @default.
• W4313325428 cites W2171406900 @default.
• W4313325428 cites W2271765448 @default.
• W4313325428 cites W2342769258 @default.
• W4313325428 cites W2579395326 @default.
• W4313325428 cites W2615205455 @default.
• W4313325428 cites W2911299769 @default.
• W4313325428 cites W2934670442 @default.
• W4313325428 cites W2948363981 @default.
• W4313325428 cites W2976967554 @default.
• W4313325428 cites W3047503436 @default.
• W4313325428 cites W3049117400 @default.
• W4313325428 cites W3063038225 @default.
• W4313325428 cites W3081685333 @default.
• W4313325428 cites W3121239749 @default.
• W4313325428 cites W3138674172 @default.
• W4313325428 cites W3200345752 @default.
• W4313325428 cites W4210417062 @default.
• W4313325428 cites W4242959903 @default.
• W4313325428 cites W4249792746 @default.
• W4313325428 cites W4254174751 @default.
• W4313325428 doi "https://doi.org/10.1001/jamanetworkopen.2022.48803" @default.
• W4313325428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36580335" @default.
• W4313325428 hasPublicationYear "2022" @default.
• W4313325428 type Work @default.
• W4313325428 citedByCount "4" @default.
• W4313325428 countsByYear W43133254282023 @default.
• W4313325428 crossrefType "journal-article" @default.
• W4313325428 hasAuthorship W4313325428A5009866488 @default.
• W4313325428 hasAuthorship W4313325428A5010840699 @default.
• W4313325428 hasAuthorship W4313325428A5015357573 @default.
• W4313325428 hasAuthorship W4313325428A5023214494 @default.
• W4313325428 hasAuthorship W4313325428A5024573751 @default.
• W4313325428 hasAuthorship W4313325428A5035759509 @default.
• W4313325428 hasAuthorship W4313325428A5045792195 @default.
• W4313325428 hasAuthorship W4313325428A5048454024 @default.
• W4313325428 hasAuthorship W4313325428A5056916024 @default.
• W4313325428 hasAuthorship W4313325428A5061175007 @default.
• W4313325428 hasAuthorship W4313325428A5061426227 @default.
• W4313325428 hasAuthorship W4313325428A5061781141 @default.
• W4313325428 hasAuthorship W4313325428A5069884819 @default.
• W4313325428 hasAuthorship W4313325428A5080485119 @default.
• W4313325428 hasAuthorship W4313325428A5085010022 @default.
• W4313325428 hasBestOaLocation W43133254281 @default.
• W4313325428 hasConcept C126322002 @default.
• W4313325428 hasConcept C143998085 @default.
• W4313325428 hasConcept C187212893 @default.
• W4313325428 hasConcept C197934379 @default.
• W4313325428 hasConcept C2776304256 @default.
• W4313325428 hasConcept C2777793932 @default.
• W4313325428 hasConcept C2778606649 @default.
• W4313325428 hasConcept C2908647359 @default.
• W4313325428 hasConcept C71924100 @default.
• W4313325428 hasConcept C99454951 @default.
• W4313325428 hasConceptScore W4313325428C126322002 @default.
• W4313325428 hasConceptScore W4313325428C143998085 @default.
• W4313325428 hasConceptScore W4313325428C187212893 @default.
• W4313325428 hasConceptScore W4313325428C197934379 @default.
• W4313325428 hasConceptScore W4313325428C2776304256 @default.
• W4313325428 hasConceptScore W4313325428C2777793932 @default.
• W4313325428 hasConceptScore W4313325428C2778606649 @default.
• W4313325428 hasConceptScore W4313325428C2908647359 @default.
• W4313325428 hasConceptScore W4313325428C71924100 @default.
• W4313325428 hasConceptScore W4313325428C99454951 @default.
• W4313325428 hasIssue "12" @default.
• W4313325428 hasLocation W43133254281 @default.
• W4313325428 hasLocation W43133254282 @default.
• W4313325428 hasLocation W43133254283 @default.
• W4313325428 hasOpenAccess W4313325428 @default.
• W4313325428 hasPrimaryLocation W43133254281 @default.

• next